Prempro Lawsuit Results in Defense Verdict
A federal jury in Virginia has handed Pfizer a defense verdict in a Prempro breast cancer lawsuit, saying that the plaintiff was properly informed about the potential side effects Prempro, a hormone replacement therapy (HRT).
The lawsuit was filed by Georgia Torkie-Tork, 65, in federal court in Alexandria, Virginia. Following trial, jurors determined that she did not establish that Wyeth failed to adequately warn about the risk of breast cancer, and returned a verdict in favor of the drug maker.
The decision is the fourth jury victory in a row for Pfizer in a Prempro suit over breast cancer. However, the drug maker has suffered several major losses at trial, which have resulted in tens of millions of dollars in compensatory damages and punitive damages after other juries determined that their Wyeth subsidiary attempted to downplay the risks associated with the medication.
Prempro is a hormone replacement therapy (HRT) that contains a combination of the drugs Provera and Premarin. The drug was originally developed by Wyeth, which was acquired by Pfizer last year.
In 2002 the National Institutes of Health released the results of studies that found women receiving HRT were at higher risk of breast cancer, strokes and heart attacks. The studies, part of the Women’s Health Initiative, sparked most of the Prempro hormone replacement therapy lawsuits currently pending throughout the country.
There are about 9,000 lawsuits over Prempro suits pending against Pfizer’s Wyeth unit. All of the lawsuits claim that the drug caused plaintiffs to develop breast cancer, and that Wyeth failed to warn patients and doctors of the potential side effects of the hormone therapy.
